| Wissenschaftl. Titel | Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT |
| Erkrankung | |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 19.12.2024 Admin07
geändert 19.12.2024 Admin07